Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

TCT 2023 | TRILUMINATE Trial: Health Status after TriClip

Severe tricuspid regurgitation (TR) has been associated with higher mortality, increased risk of hospitalization for cardiac failure (CF), reduced functionality and poor health status.  Tricuspid edge-to-edge repair (T-TEER) with TriClip effectively reduces TR with low risk of post-procedural complications. 

TCT 2023 | SWEDEHEART, evolución  a 5 años

The TRILUMINATE Pivotal trial (Trial to Evaluate Cardiovascular Outcomes in Patients Treated with the Tricuspid Valve Repair System Pivotal) compared T-TEER against medical treatment and did not find differences in mortality or CF related hospitalization at 1 year, but did observe improved health status with T-TEER.

The aim of this prospective, multicenter and randomized study was to assess the benefit of T-TEER in health status. 

Health status was measured by the Kansas questionnaire (KCCQ, Kansas City Cardiomyopathy Questionnaire) based on time reference points: at kickoff, 1 month, 6 months and 1 year. 

Read also: TCT 2023 The LIFE-BTK Trial.

A total 350 patients were randomized: 175 to receiving T-TEER and 175 to medical treatment (MT). Mean age was 78, and most patients were women. At 1 month, T-TEER resulted in improved health status and showed continuous improvement at 1 year, vs. MT. Patients undergoing T-TEER saw better survival and good health status at one year, vs MT patients (74,8% vs. 45,9%, p<0,001) with necessary number to treat (NNT) 3.5.

Conclusion

In conclusion, in this study, patients treated with T-TEER experienced improved health status vs patients receiving MT alone, and this improvement was more evident in patients with symptomatic TR. Improved health status was more evident at 1 month and was maintained at 1 year followup. 

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Health Status after Transcatheter Tricuspid-Valve Repair in Patients with Severe Tricuspid Regurgitation: Results from the TRILUMINATE Pivotal Trial.

Reference: Suzanne V. Arnold, MD MHA et al TCT 2023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...